Cantor Fitzgerald raises Abbvie stock price target to $265 on biopharma outlook
Cantor Fitzgerald raises Abbvie stock price target to $265 on biopharma outlook
Cantor Fitzgerald raises Abbvie stock price target to $265 on biopharma outlook
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.